Walleye Capital
XENE icon

Walleye Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Walleye Capital’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.65M Buy
+76,955
New +$4.27M 0.02% 870
2026
Q1 		– Sell
-19,587
Closed -$878K – 5069
2025
Q4 		$878K Buy
+19,587
New +$823K ﹤0.01% 2551
2025
Q1 		– Sell
-221,982
Closed -$8.7M – 5238
2024
Q4 		$8.7M Buy
221,982
+117,022
+111% +$4.84M 0.02% 722
2024
Q3 		$4.13M Buy
+104,960
New +$4.23M 0.01% 1322
2024
Q1 		– Sell
-5,054
Closed -$233K – 5959
2023
Q4 		$233K Sell
5,054
-120,974
-96% -$4.27M ﹤0.01% 3576
2023
Q3 		$4.31M Buy
126,028
+36,324
+40% +$1.36M 0.01% 1144
2023
Q2 		$3.45M Sell
89,704
-15,628
-15% -$621K 0.01% 961
2023
Q1 		$3.77M Buy
105,332
+18,815
+22% +$695K 0.06% 420
2022
Q4 		$3.41M Sell
86,517
-1,454
-2% -$52.9K 0.06% 369
2022
Q3 		$3.18M Sell
87,971
-73,956
-46% -$2.66M 0.06% 348
2022
Q2 		$4.93M Buy
161,927
+7,619
+5% +$230K 0.14% 175
2022
Q1 		$4.72M Buy
154,308
+82,324
+114% +$2.46M 0.13% 173
2021
Q4 		$2.25M Buy
+71,984
New +$2.15M 0.07% 303
2018
Q3 		$101K Buy
+7,647
New +$88.6K 0.05% 257

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Walleye Capital's XENE Position: Q2 2026 in Review

Walleye Capital opened a new position in Xenon Pharmaceuticals (XENE) in Q2 2026: 76,955 shares worth $4.65M. The stake represents 0.02% of the portfolio and ranks #870 among its holdings. This is a return to the name: Walleye Capital previously reported a position in XENE as recently as Q4 2025.

Walleye Capital first reported a position in XENE in Q3 2018 and has held it in 14 quarters since. The position peaked at $8.7M in Q4 2024. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Walleye Capital held 76,955 shares of Xenon Pharmaceuticals worth $4.65M as of Q2 2026.
  • Xenon Pharmaceuticals was a new Walleye Capital position in Q2 2026.
  • Xenon Pharmaceuticals made up 0.02% of Walleye Capital's portfolio in Q2 2026, its #870 holding.
  • Walleye Capital first reported a position in Xenon Pharmaceuticals in Q3 2018 and has held it in 14 quarters since.
  • Walleye Capital's Xenon Pharmaceuticals position peaked at $8.7M in Q4 2024.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.